Indeed, correlation of E-cadherin protein expression in CRC [23, 24], NSCLC [25] and urothelial [26] cancer cells with response to EGFR-targeted therapy showed that E-cadherin “loss” (with possible induction of soluble E-cadherin) points towards EGFR-targeted treatment resistance. The gene discussed is CDH1; the disease is colorectal carcinoma.